Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06735885 · ClinicalTrials.gov registry record · NA
fMRI Neurofeedback With Matter Neuroscience App
A NA study of Depression and Depression Mild, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT06735885: Recruiting NA study of Depression and Depression Mild, sponsored by Stanford University.
NCT06735885 is a NA study of Depression and Depression Mild that is actively recruiting participants, run by Stanford University. The registered enrollment target is 240 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06735885, a NA study of Depression and Depression Mild, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.
Primary Outcome
Determine the safety and efficacy of neurofeedback for treating depression through MADRS (Montgomery-Åsberg Depression Rating Scale) scale changes. The 9-item self-report version of the MADRS has an overall score range from 0-27, with higher scores corresponding to higher levels of depression.
Conditions Studied
Interventions
- DEVICE Matter Neuroscience App
- OTHER Stock Photos
- OTHER No Home Training
- DEVICE Personal Photos
- OTHER Home Training
Study Locations (1)
California
- Stanford University Brain Stimulation Lab - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2028-06-15 |
| Phase | NA |
What NCT06735885 shows while recruiting
NCT06735885 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (69% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 5 interventions - of which Matter Neuroscience App is the first listed.
NCT06735885 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06735885 about?
NCT06735885 is a clinical study titled "fMRI Neurofeedback With Matter Neuroscience App". Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.
What is the current status of trial NCT06735885?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2025-08-12. Estimated completion is 2028-06-15.
What conditions does trial NCT06735885 study?
This clinical trial studies the following conditions: Depression, Depression Mild, Depression Moderate.
What interventions are being tested in trial NCT06735885?
The interventions under investigation include: Matter Neuroscience App (DEVICE), Stock Photos (OTHER), No Home Training (OTHER), Personal Photos (DEVICE), Home Training (OTHER).
Who is sponsoring clinical trial NCT06735885?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06735885 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06735885's enrollment target sits among peer trials
240 177th of 679 higher than 494 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy